Forte Biosciences, Inc.
No SEC Form 4 filings for $FBRX in the last 30 days.
argenx (ARGX) said its subsidiary Avena Merger Sub has started a tender offer to buy all outstanding Forte Biosciences (FBRX) shares for $77.00 per share in cash, net to the seller, under a July 26, 2026 merger agreement. The offer expires Aug. 26, 2026 unless extended, and Forte’s board recommends acceptance.
Biotech Growth Trust plc said it will benefit from Argenx SE’s $2.2 billion cash takeover of Forte Biosciences. Argenx offered $77 per share, a 40.5% premium. Forte was about 3% of Biotech Growth’s portfolio. The deal is expected to add about 1.2% to net asset value, after Biotech Growth’s November 2024 entry at $5.55 per share.
Forte Biosciences (Nasdaq: FBRX) is being acquired by argenx SE in an all-cash deal valued at about $2.2 billion, or $77.00 per share, announced July 27, 2026, with expected Q3 2026 closing. The offer follows FB102 Phase Ib results in vitiligo and celiac disease, and includes FDA Fast Track for celiac. Forte raised $172.5M in April 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning FBRX (Forte Biosciences, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent FBRX coverage spans mergers & acquisitions, financial news and market movers.
FBRX faces a direct cash-outcome bid, making the stock’s value hinge on tender acceptance, conditions, and timing to merger completion.
Biotech Growth Trust plc said it will benefit from Argenx SE’s $2.2 billion cash takeover of Forte Biosciences. Argenx offered $77 per share, a 40.5% premium. Forte was about 3% of Biotech Growth’s portfolio. The deal is expected to add about 1.2% to net asset value, after Biotech Growth’s November 2024 entry at $5.55 per share.
Deal terms and timing create a near-term trading regime for FBRX tied to merger spread, regulatory risk, and deal-completion probability.
Deal announcement should dominate near-term valuation, while the described pre-deal run raises questions about timing and liquidity/volatility risk.
Near-term trading hinges on investor reaction to the equity raise and expectations for upcoming celiac and vitiligo clinical readouts.
alphai scores every news story that mentions FBRX with an AI model for sentiment and relevance, and aggregates insider trades from Forte Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
argenx (ARGX) said its subsidiary Avena Merger Sub has started a tender offer to buy all outstanding Forte Biosciences (FBRX) shares for $77.00 per share in cash, net to the seller, under a July 26, 2026 merger agreement. The offer expires Aug. 26, 2026 unless extended, and Forte’s board recommends acceptance.
5 min readBiotech Growth Trust plc said it will benefit from Argenx SE’s $2.2 billion cash takeover of Forte Biosciences. Argenx offered $77 per share, a 40.5% premium. Forte was about 3% of Biotech Growth’s portfolio. The deal is expected to add about 1.2% to net asset value, after Biotech Growth’s November 2024 entry at $5.55 per share.
3 min readForte Biosciences (Nasdaq: FBRX) is being acquired by argenx SE in an all-cash deal valued at about $2.2 billion, or $77.00 per share, announced July 27, 2026, with expected Q3 2026 closing. The offer follows FB102 Phase Ib results in vitiligo and celiac disease, and includes FDA Fast Track for celiac. Forte raised $172.5M in April 2026.
6 min readArgenx (ARGX) said it will acquire Forte Biosciences (FBRX) for $77 per share, announced July 27. The article says FBRX began unusual price movement on June 29, weeks before the deal, and notes similar trading activity in ARGX. It cites company valuations of about $1.06 billion for FBRX and $54.57 billion for ARGX.
6 min readThe article discusses Argenx’s $2.2 billion bet via a deal with Forte Biosciences, focused on Forte’s FB102 anti-CD122 antibody for autoimmune diseases including celiac, vitiligo, and alopecia areata. It notes early celiac data and expected clinical readouts later in the year, while citing share pressure from an equity raise and delayed vitiligo timing.
3 min readStocks slipped from early highs as chipmakers and AI-infrastructure shares fell. The iShares Semiconductor ETF (SOXX) fell over 3%, with Sandisk (SNDK) down more than 11% and AMD and Western Digital down over 6%. Crude dropped about 6%, lifting T-notes and lowering 10-year breakeven inflation. Software stocks rose; Workday gained over 8%.
6 min readArgenx agreed to acquire Forte Biosciences for $2.2B to expand its immunology portfolio. The deal centers on Forte’s anti-CD122 antibody FB102, which showed Phase Ib vitiligo results with 29.6% mean FVASI improvement at week 24 (p=0.020). Argenx plans a $77 per share cash tender offer, expected to close in Q3.
6 min readU.S. stocks ended mixed as investors weighed Middle East de-escalation hopes and upcoming Fed and GDP data. Oil fell to a week low, pressuring ExxonMobil, Chevron, ConocoPhillips and Occidental. Airlines and cruise lines rose, including United, Delta, Southwest, Carnival, Norwegian and Royal Caribbean. Tech results and reports from Microsoft, Apple, Meta, Amazon and Alphabet were in focus; Nvidia dropped after a Wall Street Journal report. Forte Biosciences jumped on Argenx’s $2.2B buyout; Baker
2 min readargenx agreed to acquire Forte Biosciences for about $2.2bn total equity value. The deal, approved by both boards, is expected to close in Q3 2026 subject to conditions. argenx will tender for all Forte shares at $77 each, an ~86% premium. Forte’s lead asset FB102 (anti-CD122) is in Phase Ib and plans Phase II data in 2H 2026.
4 min readargenx agreed to acquire Forte Biosciences for about $2.2bn in cash. It will launch a tender offer at $77 per Forte share, an 86% premium to the 9 July VWAP after Phase 1b vitiligo results. The deal is expected to close in Q3, subject to tendering and US antitrust review. Forte’s lead FB102 targets CD122.
7 min read
